Efficacy of frameless stereotactic radiotherapy for the treatment of presumptive canine intracranial gliomas: A retrospective analysis (2014-2017)
Efficacy of frameless stereotactic radiotherapy for the treatment of presumptive canine intracranial gliomas: A retrospective analysis (2014-2017)
复制标题
DOI：
10.1111/vco.12573
复制
发表时间：
2020-04-23
影响因子：
2.1
通讯作者：
Yang, Jun
中科院分区：
文献类型：
--
作者：
Moirano, Steven J.;Dewey, Curtis W.;Yang, Jun
使用传统的多分割放射治疗神经胶质肿瘤的文献中有很好的记录。最近，立体定向放射治疗（SRT）已变得更加广泛，允许低分割协议，但是，其在治疗犬颅内胶质瘤的有用性在很大程度上是不确定的。我们进行了一项回顾性分析，包括21只被诊断为颅内胶质瘤的狗，这些狗接受了一个或多个疗程的8至10戈伊射波刀SRT治疗。本研究的目的是评价与使用SRT治疗犬颅内胶质瘤相关的疗效、安全性和预后因素。所有犬的总体MST为636天（d）。用所述SRT方案的一个疗程治疗的狗具有258天的MST，而用>1个疗程治疗的那些狗具有865天的MST（P = 0.0077对数秩，0.0139 Wilcoxon）。接受一个疗程SRT治疗的接受辅助化疗的犬的MST>658天，并且比未接受化疗的犬（MST，230天）显著更长（P = 0.0414对数秩，0.0453 Wilcoxon）。最常见的不良事件包括3/21只犬的假定一过性脱髓鞘，所有患者均成功接受皮质类固醇治疗。这项研究提供的证据表明，SRT在延长颅内胶质瘤犬的生存期方面是有效的，并且可能提供与传统分次方案相似的结果，同时减少医院就诊和麻醉发作的次数。此外，患者似乎可以安全地接受多轮SRT治疗，从而改善生存时间。
The use of conventional multi-fractionated radiotherapy for the treatment of glial tumours is well documented in the literature. Recently, stereotactic radiotherapy (SRT) has become more widely available allowing for hypo-fractionated protocols; however, its usefulness in the treatment of canine intracranial gliomas is largely undetermined. We conducted a retrospective analysis, including 21 dogs diagnosed with presumptive intracranial gliomas treated with one or more courses of three fractions of 8 to 10 Gy CyberKnife SRT. The objective of this study was to evaluate the efficacy, safety and prognostic factors associated with the use of SRT for the treatment of canine intracranial gliomas. Overall MST for all dogs was 636 days (d). Dogs treated with one course of the described SRT protocol had a MST of 258 days while those treated with >1 course had a MST of 865 days (P = .0077 log rank, 0.0139 Wilcoxon). Dogs treated with one course of SRT who received adjuvant chemotherapy had a MST of >658 days and lived significantly longer than those who did not receive chemotherapy (MST, 230 days) (P = .0414 log rank, 0.0453 Wilcoxon). The most common adverse event included presumptive transient demyelination in 3/21 dogs, which was treated successfully with corticosteroids in all patients. This study provides evidence that SRT is effective in prolonging survival in dogs with intracranial gliomas, and may provide similar results to conventional fractionated protocols, while decreasing the number of hospital visits and anaesthetic episodes. Additionally, it appears that patients can be safely treated with multiple rounds of SRT resulting in improved survival times.